Pds Biotechnology Corporation · NASDAQ:PDSB

Pds Biotechnology — Q1 2026 Earnings Presentation

21 slides from Pds Biotechnology's earnings presentation, May 13, 2026

  1. Slide 1: Precision Designed Science for Cancer Patients

    Precision Designed Science for Cancer Patients NASDAQ: PDSB April 2026 1 © 2026 PDS Biotechnology. All Rights Reserved.

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corpo

  3. Slide 3: Targeting HPV16+ Cancers

    Targeting HPV16+ Cancers REGISTRATIONAL TRIAL COMPELLING CLINICAL DATA POTENTIAL ACROSS CANCERS Phase 3 VERSATILE-003 pivotal trial 39.3 months median overall survival 4 clinical trials completed FDA alignment on Progression- 12-18 months for current standard Partnerships with leading cancer Free-Su

  4. Slide 4: HPV16+ Tumors Represent Largest and Fastest Growing Type of HNSCC

    HPV16+ Tumors Represent Largest and Fastest Growing Type of HNSCC 30,000 Annual Number of Oropharyngeal Cancer Cases HPV16+ HNSCC Rapidly Increasing in US/EU 25,000 • Poor uptake of HPV vaccine2,3 20,000 HPV16+ 15,000 PDS Biotech focus • Changing sexual behavior4 10,000 • Unique pathophysiology of H

  5. Slide 5: HPV16+ Patients Have No Targeted Therapies; Worse Clinical Outcomes

    HPV16+ Patients Have No Targeted Therapies; Worse Clinical Outcomes PUBLISHED EVIDENCE CURRENT STANDARD OF CARE Two head-to-head studies demonstrate that HPV16-positive patients have statistically worse Keytruda® (pembrolizumab) + chemotherapy survival compared to other patient groups: median surviv

  6. Slide 6: The Versamune Platform Provides Mechanism for Targeted Immune Attack

    The Versamune® Platform Provides Mechanism for Targeted Immune Attack • Proprietary immunotherapy platform R-DOTAP forms Nanoparticles sized 100- designed to generate cytotoxic CD8+ T-cell spherical bilayers in 200nm to promote uptake aqueous environment by the immune system responses against specif

  7. Slide 7: PDS0101: Training the Immune System to Find and Destroy HPV16+ Tumors

    PDS0101: Training the Immune System to Find and Destroy HPV16+ Tumors8 LYMPH NODE TUMOR Dendritic Cell Immune HPV16 E6 & E7 Checkpoint Inhibitor Versamune® + HPVmix (PDS0101) MHC class I CD8+ killer T cell Targeted CD8+ T Cells Tracks to Tumor Versamune® CD4+ Activated CD8+ MHC class II helper T cel

  8. Slide 8: Pipeline Expansion Across Multiple Indications

    Pipeline Expansion Across Multiple Indications Partnerships with Leading Cancer Research Institutions Therapy / Treatment Indication P2 P3 Partner PDS0101 + pembrolizumab vs. HPV16-positive recurrent/metastatic head FDA Fast Track pembrolizumab (VERSATILE-003) and neck cancer (In progress) Versamune

  9. Slide 9: Lead Clinical Program Evaluating PDS0101 in Combination with Checkpoint Inhibitors

    Lead Clinical Program Evaluating PDS0101 in Combination with Checkpoint Inhibitors VERSATILE-002: PDS0101 + Pembrolizumab in 1L HPV16+ R/M HNSCC Key Entry Study Study Criteria for ICI Endpoints Treatment Design Naïve Subjects PDS0101 HPV16-positive R/M Single-arm study Primary HNSCC tumors Best over

  10. Slide 10: PDS0101 + Pembrolizumab: mOS of 39.3 Months

    PDS0101 + Pembrolizumab: mOS of 39.3 Months9 12-18 Months mOS is Benchmark with Pembrolizumab and Pembrolizumab + Chemotherapy1 Durable Survival: 11 Patients Surpassed 30 Months mOS = Median Overall Survival. No head-to-head studies have been performed. 10

  11. Slide 11: PDS0101: Near or Complete Tumor Shrinkage

    PDS0101: Near or Complete Tumor Shrinkage in Difficult-to-Treat Patients9 • 63% with CPS 1-199 • Confirmed disease control rate of 77.4% • ORR of 35.8% • 21% of patients had tumor regression of 90-100% *Investigator assessment. 11

  12. Slide 12: PDS0101: Well-Tolerated with a Low Incidence of Adverse Events

    PDS0101: Well-tolerated with a Low Incidence of Adverse Events9 Treatment related adverse events (TRAEs) Most common Non-Injection n (%) n (%) by Grade in ICI naïve and resistant patients Site Reaction TRAEs Any Combination TRAE 76 (87.4) Fatigue 30 (34.5) Grade 1 40 (46.0) Headache 13 (14.9) Grade

  13. Slide 13: VERSATILE-003: Pivotal Phase 3 in Progress

    VERSATILE-003: Pivotal Phase 3 in Progress PDS0101 + pembrolizumab in 1L HPV16-positive R/M HNSCC Interim Interim Final Analysis 1 Analysis 2 Analysis Study Start (PFS) (PFS) (mOS) PDS0101 + Pembrolizumab Patient Recruitment Survival Follow-up Pembrolizumab Patient Recruitment Survival Follow-up Ran

  14. Slide 14: Well-Positioned in 1L HPV16+ R/M HNSCC

    Well-Positioned in 1L HPV16+ R/M HNSCC PDS0101: Only Subcutaneous Combination Therapy in Late-stage Development for 1L HPV16+ HNSCC Combinations with pembrolizumab Genmab10 Bicara11 BioNTech12 PDS Biotech 39.3 months Median OS Not disclosed 21.3 months 22.6 months 95% CI (23.9, NE) Population All co

  15. Slide 15: PDS01ADC: Novel Investigational Tumor Targeting IL-12 Immunocytokine

    PDS01ADC: Novel Investigational Tumor Targeting Interleukin-12 (IL-12) Immunocytokine13,14 Encouraging tolerability and potency demonstrated in over 330 patients NHS76 THE CHALLENGE IL-12 is a powerful NK* and T cell activator that helps fight cancer, but Tumor Necrosis Targeting Antibody – injectin

  16. Slide 16: Upcoming Catalysts

    Upcoming Catalysts 1Q 2026 2Q 2026 2H 2026 1H 2027 2H 2027 Adoption of Amended Enrollment completion VERSATILE-003 Protocol (FDA) PFS data readout (Head and (Submission of interim neck cancer) data to FDA) PDS01ADC + docetaxel PDS01ADC + HAIP Final Data Readout PDS01ADC + HAIP Stage 1 PDS01ADC + in

  17. Slide 17: Global IP Portfolio Covers Key Commercial Markets

    Global IP Portfolio Covers Key Commercial Markets 13 Patent Families COVERAGE Composition and method claims protecting both platform technology and product candidates PDS0101 EXCLUSIVITY 8 KEY MARKETS 2041/2042 North America Europe Middle East Asia Pacific USA Canada Mexico EU/UK Israel China Japan

  18. Slide 18: PDS Platform is a Significant Value Creation Opportunity

    PDS Platform is a Significant Value Creation Opportunity Current Focus Next Steps Commercialization Expansion into Pivotal Studies in HPV16+ HNSCC Types Path to Commercialization Various Indications 39.3 Locally advanced IMMUNOCERV cervical cancer Median Overall Survival (12–18 mo. benchmark)* TOTAL

  19. Slide 19: The PDS Opportunity

    The PDS Opportunity World-Class Research Partners NCI, Mayo Clinic, MD Anderson and leading cancer centers The only investigational therapy with studies externally funded, independently validated in Phase 3 with 30+ months median Global IP Protection survival in 1L HPV16+ R/M HNSCC 13 patent familie

  20. Slide 20: Thank You

    Thank You NASDAQ: PDSB April 2026 20 © 2026 PDS Biotechnology. All Rights Reserved.

  21. Slide 21: References

    References 1. Harrington, KJ, Burtness B, Greil R, et al. Keytruda With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol. 2022;41:790-802. https://doi.org/10.1200/JCO.21.02508. 2. Damgacioglu H,

PDS Biotechnology — Q1 2026 Earnings Presentation on 6ix